Oxford Biomedica (LON:OXB) Price Target Raised to GBX 800

Oxford Biomedica (LON:OXB) had its price objective lifted by Deutsche Bank Aktiengesellschaft from GBX 735 to GBX 800 in a research report released on Friday, Marketbeat reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Separately, Canaccord Genuity Group reiterated a “buy” rating and set a GBX 451 price objective on shares of Oxford Biomedica in a research report on Tuesday, October 7th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of GBX 606.40.

Oxford Biomedica Stock Down 1.2%

Shares of LON OXB opened at GBX 741.87 on Friday. The company has a market cap of £895.82 million, a price-to-earnings ratio of -20.48 and a beta of 1.09. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. Oxford Biomedica has a 12 month low of GBX 232.50 and a 12 month high of GBX 765. The stock has a 50-day moving average price of GBX 627.54 and a two-hundred day moving average price of GBX 550.77.

Insider Activity at Oxford Biomedica

In other news, insider Heather Preston purchased 6,175 shares of Oxford Biomedica stock in a transaction dated Monday, October 20th. The shares were bought at an average cost of GBX 593 per share, for a total transaction of £36,617.75. Insiders own 34.83% of the company’s stock.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.